Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

House Panel May Subpoena FDA Investigators To Address Ketek Safety Study

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency foot-dragging over questions regarding approval of the Sanofi-Aventis antibiotic leads House Energy and Commerce subcommittee to consider forcing testimony.
Advertisement

Related Content

House Subpoenas FDA Staffers In Ketek Investigation
House Subpoenas FDA Staffers In Ketek Investigation
Sanofi-Aventis Failed To Act Against Ketek Clinical Investigator, FDA Charges
FDA Safety Decisions On Ketek To Get Formal Review By House Committee
FDA Safety Decisions On Ketek To Get Formal Review By House Committee
Ketek Act I: FDA Updates Label, Touts Process On Eve Of Hearing
Von Eschenbach Nomination Clears Senate Handily

Topics

Advertisement
UsernamePublicRestriction

Register

PS066796

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel